SurgiVance, a leading innovator in developing AI-driven, direct-to-digital confocal pathology, announced today that Michael Li, PhD has been appointed Chief Executive Officer.
NEW YORK – January 9, 2023 – (Newswire.com)
“On behalf of the Board, we are very pleased to welcome Dr. Li to SurgiVance as the company is moving into a new phase of product development and commercialization, and to further its leadership position in advancing and innovating healthcare with the next generation direct-to-digital confocal pathology,” said Dr. Gareau, the founder and Chairman of Board at SurgiVance. “We are delighted that Dr. Li can join the SurgiVance team, and excited to have him as a partner on our journey. He is not only an experienced technology executive, but also a great strategic navigator, which is key in this exciting and rapidly evolving field.”
Dr. Li brings with him many years of rich leadership experience in medical devices, healthcare, and technology, from R&D, to new product commercialization, to general management. He has held senior management positions in major multinationals such as Siemens Medical, as well as numerous medical device and IVD startups such as Neural Analytics. Dr. Li received his doctoral degree in physics from the University of Washington, Seattle.
“I am impressed by the technology advancement and significant innovations by Dr. Gareau and the SurgiVance team and I am excited to lead the team in moving the technology to market. Pathology is a corner stone of medical care. Hopefully, we will ease the existing true pain points experienced by physicians, improve patient care, and save more lives.” said Dr. Li.
Chief Executive Officer
Press Release Service